Almac's New Headquarters Introduces Scheduled I-V Substance Capabilities

SOUDERTON, Pennsylvania, February 28, 2011 - Packaging, storage and distribution of schedule I-V controlled substances
is now a fully functional capability of Almac's new North American
Headquarters in Souderton, PA. As the phased transition nears its end, the
portfolio of services and capacity offered to customers continues to grow as
a result of the $120 million investment.

Storage of controlled materials is located in a highly secured
temperature monitored cage and vault. Both locations meet DEA (Drug
Enforcement Administration) requirements in addition to providing
substantially greater capacity. The total 3,980 square feet of storage space
comes as a response to demand expressed by both the industry and existing
clients. This, as well as expansive growth in areas of storage for ambient,
refrigerated and frozen products, is part of Almac's ongoing mission to
ensure drugs get to market faster.

Dave Setley, Head of Business Development, commented on the addition by
saying: "The expanded storage and distribution of controlled drug product
from the NAHQ further solidifies Almac's position as a leader in the clinical
supply arena."

Almac's facility growth has also allowed the Company to offer a broad
range of pharmaceutical development services from the US headquarters site -
all under one roof, mirroring the successful mix of services offered by the
Global Headquarters in Northern Ireland. Clients can now carry out their
trial supply services from the Souderton (PA) location, as well as IWR/IVRS
and analytical services if needed. This proves to be an unparalleled
advantage in the market and sets Almac aside from its competitors in the
industry.

As the phased transition nears its end, Almac is busily working around
the clock to make sure current projects continue without interruption. Almac
invites existing and prospective clients, as well as the media, to schedule
tours of the facility or learn more by visiting: www.almacgroup.com.

About Almac Group

The Almac Group provides a broad range of services from R&D, biomarker
discovery and development, API manufacture, formulation development, clinical
trial supply and IXRS technology (IVRS/IWRS), to commercial-scale
manufacture. Almac provides services to more than 600 companies, including
all the world leaders in the pharmaceutical and biotech sectors.

The company employs over 3,000 individuals and is headquartered in
Craigavon, Northern Ireland. US operations are based in Pennsylvania, North
Carolina and California. Almac has now moved into its new $120m North
American Headquarters located in Souderton PA.

For more information about the Almac Group, please visit
www.almacgroup.com or e-mail info@almacgroup.com

www.defacto.com

Alex Heeley, Account Manager, De Facto Communications, 330 High Holborn, London WC1V 7QD, Telephone: +44(0)207-861-3838, Direct: +44(0)207-861-3043, Fax: +44(0)207-861-3839, E-mail: A.heeley at defacto.com